NASDAQ
18.09.26 | 21:59
21,080 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BTIG hebt Kursziel für Cullinan Oncology nach Studiendaten an | 8 | Investing.com Deutsch | ||
| Mo | BTIG raises Cullinan Oncology stock price target on trial data | 2 | Investing.com | ||
| Mo | Cullinan Oncology Aktie: TD Cowen bekräftigt Kaufempfehlung | 1 | Investing.com Deutsch | ||
| Mo | Stifel bekräftigt Kaufempfehlung für Cullinan Oncology Aktie nach Studiendaten | 1 | Investing.com Deutsch | ||
| Mo | Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen | 1 | Investing.com | ||
| Mo | Stifel reiterates Cullinan Oncology stock Buy rating on trial data | 1 | Investing.com | ||
| Mo | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.08. | UBS raises Cullinan Oncology stock price target to $27 on trial data | 4 | Investing.com | ||
| 12.08. | Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health | 2.558 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| 06.08. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results | 777 | GlobeNewswire (Europe) | CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase... ► Artikel lesen | |
| 06.08. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 06.08. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.07. | Cullinan Therapeutics: Positive FDA-Rückmeldung treibt Aktie an | 4 | Investing.com Deutsch | ||
| 28.07. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML | 346 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; "Cullinan"), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class... ► Artikel lesen | |
| 16.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.06. | William Blair reiterates Cullinan Oncology stock rating on trial data | 3 | Investing.com | ||
| 10.06. | William Blair bestätigt "Outperform"-Rating für Cullinan Oncology nach Studiendaten | 1 | Investing.com Deutsch | ||
| 10.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases | 10 | GlobeNewswire (USA) | ||
| 08.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,022 | -1,26 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,664 | +1,96 % | Cardiol Therapeutics Inc: Cardiol receives $7M (U.S.) from warrant exercise | ||
| ARBUTUS BIOPHARMA | 4,320 | -0,92 % | Arbutus Biopharma Corp-Aktie im Check am 17.09. (08:40 Uhr): Meine aktuelle Lageeinschätzung | ||
| CARDIFF ONCOLOGY | 1,120 | -6,43 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| ALDEYRA | 1,170 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DENALI THERAPEUTICS | 17,550 | +2,18 % | Denali Therapeutics: Markteinführung von Avlayah gewinnt an Fahrt | ||
| ABCELLERA BIOLOGICS | 10,920 | 0,00 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 24,770 | -0,56 % | Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ | Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity... ► Artikel lesen | |
| AC IMMUNE | 2,300 | -0,22 % | AC Immune SA: AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 | AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,112 | -4,39 % | Coherus auf Morgan Stanley Konferenz: Onkologie-Strategie gewinnt an Dynamik | ||
| CYTOMX THERAPEUTICS | 2,420 | +0,88 % | CytomX auf Morgan Stanley Konferenz: Strategie für fortgeschrittenes Kolorektalkarzinom im Fokus | ||
| CYBIN | 11,120 | +3,35 % | Helus Pharma auf Morgan Stanley Konferenz: Strategie zielt auf breiteren Depressionsmarkt | ||
| AGENUS | 6,400 | -6,57 % | Agenus Inc.: Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,040 | +0,06 % | Arcturus to present Phase 2 data for OTC deficiency treatment |
CULLINAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 21,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.